Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Liver Diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,944 result(s) found for: Liver Diseases. Displaying page 7 of 198.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2012-003977-24 Sponsor Protocol Number: SGI-110-03 Start Date*: 2014-03-20
    Sponsor Name:Astex Pharmaceuticals Inc
    Full Title: A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment with Sorafenib
    Medical condition: Advanced Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001381-42 Sponsor Protocol Number: IMMULAB Start Date*: 2019-01-25
    Sponsor Name:Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
    Full Title: IMMULAB – A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC)
    Medical condition: early stage hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002755-29 Sponsor Protocol Number: CA209-9DX Start Date*: 2018-11-19
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or ...
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004283-37 Sponsor Protocol Number: 9785-CL-3021 Start Date*: 2015-10-20
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma
    Medical condition: Male and female subjects with HCC of any etiology who have progressed on or were intolerant to sorafenib or other anti-VEGF therapy in the advanced setting
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001983-31 Sponsor Protocol Number: GT-031 Start Date*: 2021-05-04
    Sponsor Name:Galectin Therapeutics Inc.
    Full Title: A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Es...
    Medical condition: Esophageal Varices in NASH Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10009214 Cirrhosis of liver without mention of alcohol LLT
    21.1 100000004856 10055489 Esophageal varices in cirrhosis of liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001969-33 Sponsor Protocol Number: TAK-242-2001 Start Date*: 2020-05-28
    Sponsor Name:Akaza Bioscience Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Proof-of-Concept, Phase 2a Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-242 in Subj...
    Medical condition: Acute Alcoholic Hepatitis Causing Decompensation of Alcohol related Cirrhosis and Acute-on-Chronic Liver Failure
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10001627 Alcoholic liver disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003932-22 Sponsor Protocol Number: IM025-017 Start Date*: 2022-10-04
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic ...
    Medical condition: Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10019669 Hepatic fibrosis and cirrhosis HLT
    20.1 100000004871 10064844 Compensated cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) DE (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002860-29 Sponsor Protocol Number: ONC-2019-002 Start Date*: 2019-12-12
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune checkpoint inhibitors: A Phase II study (Immunocabo).
    Medical condition: Hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012916-41 Sponsor Protocol Number: CICL670EDE08T Start Date*: 2010-01-12
    Sponsor Name:CROLLL GmbH
    Full Title: The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (NASH) - a prospective open-label phase I/II trial
    Medical condition: To assess the clinical and biological activity of Deferasirox in patients with NASH and increased iron storage / disturbed distribution of iron on liver function and liver histology
    Disease: Version SOC Term Classification Code Term Level
    14.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004141-24 Sponsor Protocol Number: 228763 Start Date*: 2018-01-26
    Sponsor Name:Brighton and Sussex University Hospitals NHS Trus
    Full Title: A phase IV, open-label pilot study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised backgro...
    Medical condition: Non-alcoholic fatty liver disease in people living with well-controlled HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver PT
    20.1 100000004862 10008919 Chronic HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-003575-21 Sponsor Protocol Number: Start Date*: 2017-07-25
    Sponsor Name:MRC Clinical Trials Unit at UCL
    Full Title: A multicentre, 48 week randomised controlled factorial trial of adding maraviroc and/or metformin for hepatic steatosis in HIV-1-infected adults on combination antiretroviral therapy.
    Medical condition: Hepatic steatosis in adults with chronic HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-000217-32 Sponsor Protocol Number: VK2809-202 Start Date*: 2021-02-16
    Sponsor Name:VIKING THERAPEUTICS, INC.
    Full Title: VK2809 A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VK2809 ADMINISTERED FOR 52 WEEKS FOLLOWED BY A 4-WEEK OFF-DRUG...
    Medical condition: non-alcoholic steatohepatitis with fibrosis
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    20.0 10019805 - Hepatobiliary disorders 10019668 Hepatic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003876-38 Sponsor Protocol Number: EDP305-102 Start Date*: 2020-08-19
    Sponsor Name:Enanta Pharmaceuticals Inc.
    Full Title: A Phase 2b Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects with Liver-Biopsy Proven Non-Alcoholic Steatohepatitis (NASH) (ARGON-2)
    Medical condition: Non-alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-002045-36 Sponsor Protocol Number: Start Date*: 2016-11-17
    Sponsor Name:University of Oxford, Clinical Trials and Research Governance
    Full Title: Lifestyle induced weight loss and Liraglutide in the treatment of non-alcoholic steatohepatitis (NASH)
    Medical condition: Non-alcoholic steatohepatitis (NASH)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002478-30 Sponsor Protocol Number: FLUSH Start Date*: 2013-06-05
    Sponsor Name:Leiden University Medical Center
    Full Title: Arterial perfusion with t-PA in donation after cardiac death (DCD) to reduce the incidence of non-anastomotic biliary strictures after orthotopic liver transplantation
    Medical condition: Biliary strictures after orthotopic liver transplantation caused by microthrombi in the donorliver during procurement
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004431-79 Sponsor Protocol Number: CC-90001-NASH-001 Start Date*: 2019-11-15
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSEFINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND LIVE...
    Medical condition: Confirmed diagnosis of NASH and Stage 3 or Stage 4 fibrosis based upon the NASH Clinical Research Network (CRN) Histologic Scoring System and a nonalcoholic fatty liver disease (NAFLD) Activity Sco...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) ES (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001001-91 Sponsor Protocol Number: XL184-309 Start Date*: 2013-08-12
    Sponsor Name:Exelixis, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib.
    Medical condition: Subjects with Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) DE (Completed) NL (Ongoing) ES (Completed) IE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003094-21 Sponsor Protocol Number: 2831 Start Date*: 2021-02-11
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Strategy Option in Combined locoregional treatment (Strategy CHemoEMbolization & Ablation) of patients with hepatocellular carcinoma: A Non-inferiority Randomized Multicenter Trial
    Medical condition: Uninodular or multinodular (maximum 3 nodules) HCC with target lesion(s) = 3 cm and < 7 cm in size, not suitable for surgery, with unilobar Disease, with liver cirrhosis classified as Child-Pugh sc...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10062040 Liver operation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003164-21 Sponsor Protocol Number: 652-2-203 Start Date*: 2015-01-05
    Sponsor Name:Tobira Therapeutics, Inc., a subsidiary of Allergan plc
    Full Title: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis
    Medical condition: Nonalcoholic Steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) IT (Completed) DE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001985-86 Sponsor Protocol Number: JX594-HEP024 Start Date*: 2016-09-29
    Sponsor Name:SillaJen Inc.
    Full Title: A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carc...
    Medical condition: Advanced Hepatocellular Carcinoma (HCC) without prior systemic therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PT (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Feb 13 15:12:56 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA